A new systemic nutrition-inflammation index predicted perioperative non-small cell lung cancer outcomes better than current ...

The following is a summary of "Clinicopathologic and genomic analyses of SMARCA4-mutated non-small cell lung carcinoma ...

Microbio Co., Ltd. (TPEx: 4128) today announced promising results from an exploratory clinical trial assessing MS-20 in ...

HONG KONG, China I March 16, 2025 I Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been ...

In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that ...

The updated guidelines note that patients with stage IV NSCLC who have EGFR exon 19 deletions or exon 21 L858R substitutions can receive osimertinib plus platinum doublet chemotherapy or amivantamab ...

In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that measures the presence of ...

Approval based on ADRIATIC Phase III trial results which showed a 27% reduction in the risk of death versus placebo ...

Global Bispecific Antibodies market size to surpass US$ 50 Billion By 2030 Says Kuick Research Delhi, March 17, 2025 (GLOBE ...

The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...

The table is a review of notable updates that occurred in February 2025 for investigational products in development.